Pickering 2018.

Study characteristics
Methods	Design: parallel Duration: 4 weeks Assessment: baseline and post‐interventions Country: France
Participants	Pain condition: fibromyalgia Population: adult women with fibromyalgia Minimum pain intensity: no Inclusion criteria Fibromyalgia meeting ACR criteria Exclusion criteria Physical or mental health comorbidities Total participants randomised: 54 Age in years (mean, SD): 46.7 (10.6) Gender: 54/54 were female Pain duration in months (mean): 71.9
Interventions	Placebo n = 25 Inert Matched dosing Milnacipran 100 mg n = 29 SNRI Fixed dose
Outcomes	Pain intensity Moderate pain relief AEs SAEs Withdrawal
Missing data methods	Completer analysis only
Funding source	Non‐pharmaceutical: "We thank the Apicil foundation for their financial support"
Conflicts of interest	The study authors report no conflicts of interest in this work.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The randomisation sequence was generated using random blocks.
Allocation concealment (selection bias)	Low risk	Treatment allocation followed a predefined randomisation plan and was conducted by a person independent from the protocol.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, identical study drugs with matched dosing
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	High risk	Completer analysis only Attrition: Total: 6/54 (11.1%) Placebo: 1/29 (3.5%) Milnacipran 100 mg: 5/25 (20.0%)
Selective reporting (reporting bias)	Low risk	Study protocol published: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393595/ All outcomes matched those published
Other bias	Low risk	No other sources of bias were identified.